» Articles » PMID: 24263102

MiRNA-296-3p-ICAM-1 Axis Promotes Metastasis of Prostate Cancer by Possible Enhancing Survival of Natural Killer Cell-resistant Circulating Tumour Cells

Overview
Journal Cell Death Dis
Date 2013 Nov 23
PMID 24263102
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Natural killer (NK) cells are important in host to eliminate circulating tumour cells (CTCs) in turn preventing the development of tumour cells into metastasis but the mechanisms are very poorly defined. Here we find that the expression level of miR-296-3p is much lower in the non-metastatic human prostate cancer (PCa) cell line P69 than that in the highly metastatic cell line M12, which is derived from P69. We demonstrate that miR-296-3p directly targets and inhibits the expression of intercellular adhesion molecule 1 (ICAM-1) in the malignant M12. The data from clinical tissue microarrays also show that miR-296-3p is frequently upregulated and ICAM-1 is reversely downregulated in PCa. Interestingly, ectopic expression of miR-296-3p in P69 increases the tolerance to NK cells whereas knockdown of miR-296-3p in M12 reduces the resistance to NK cells, which both phenotypes can be rescued by re-expression or silencing of ICAM-1 in P69 and M12, respectively. These results are also manifested in vivo by the decrease in the incidence of pulmonary tumour metastasis exhibited by knockdown of miR-296-3p in M12 when injected into athymic nude mice via tail vein, and consistently down-expression of ICAM-1 reverses this to increase extravasation of CTCs into lungs. Above results suggest that this newly identified miR-296-3p-ICAM-1 axis has a pivotal role in mediating PCa metastasis by possible enhancing survival of NK cell-resistant CTC. Our findings provide novel potential targets for PCa therapy and prognosis.

Citing Articles

NK Cell-Microbiota Interaction Biomarker Strategy: Advancing Prostate Cancer Management.

Fanijavadi S, Hansen T, Zedan A Biomolecules. 2025; 15(2).

PMID: 40001576 PMC: 11852595. DOI: 10.3390/biom15020273.


Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives.

Shi X, Wang X, Yao W, Shi D, Shao X, Lu Z Signal Transduct Target Ther. 2024; 9(1):192.

PMID: 39090094 PMC: 11294630. DOI: 10.1038/s41392-024-01885-2.


Extracellular vesicle-encapsulated microRNA-296-3p from cancer-associated fibroblasts promotes ovarian cancer development through regulation of the PTEN/AKT and SOCS6/STAT3 pathways.

Sun L, Ke M, Yin M, Zeng Y, Ji Y, Hu Y Cancer Sci. 2023; 115(1):155-169.

PMID: 37972389 PMC: 10823290. DOI: 10.1111/cas.16014.


Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis.

Dahut M, Fousek K, Horn L, Angstadt S, Qin H, Hamilton D J Immunother Cancer. 2023; 11(9).

PMID: 37678915 PMC: 10496692. DOI: 10.1136/jitc-2023-007386.


Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity.

Dos Reis F, Jeronimo C, Correia M Front Immunol. 2023; 14:1152572.

PMID: 37090711 PMC: 10113550. DOI: 10.3389/fimmu.2023.1152572.


References
1.
Bryceson Y, March M, Barber D, Ljunggren H, Long E . Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med. 2005; 202(7):1001-12. PMC: 2213171. DOI: 10.1084/jem.20051143. View

2.
Smyth M, Swann J, Kelly J, Cretney E, Yokoyama W, Diefenbach A . NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med. 2004; 200(10):1325-35. PMC: 2211920. DOI: 10.1084/jem.20041522. View

3.
Hu G, Gong A, Liu J, Zhou R, Deng C, Chen X . miR-221 suppresses ICAM-1 translation and regulates interferon-gamma-induced ICAM-1 expression in human cholangiocytes. Am J Physiol Gastrointest Liver Physiol. 2010; 298(4):G542-50. PMC: 2853302. DOI: 10.1152/ajpgi.00490.2009. View

4.
Fidler I . The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3(6):453-8. DOI: 10.1038/nrc1098. View

5.
Jacob K, Sollier C, Jabado N . Circulating tumor cells: detection, molecular profiling and future prospects. Expert Rev Proteomics. 2007; 4(6):741-56. DOI: 10.1586/14789450.4.6.741. View